2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Thursday, March 30, 2023

5:10PM-5:40PM: Abstract Number: 017

Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study

Poster Breakout 2 - JIA & Uveitis: Genetics, Clinical & Therapeutic Aspects

5:10PM-5:40PM: Abstract Number: 011

The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center

Poster Breakout 1 - Lupus: Genetics, Epigenetics, & Social Determinants

5:10PM-5:40PM: Abstract Number: 012

Thrombotic Microangiopathic Changes in Kidney Biopsies of Childhood-Onset Systemic Lupus Erythematous Patients with and Without Severe Hematologic Disturbances

Poster Breakout 1 - Lupus: Genetics, Epigenetics, & Social Determinants

5:10PM-5:40PM: Abstract Number: 018

Using the Electronic Health Record to Identify Subjects with Rheumatic Disease

Poster Breakout 2 - JIA & Uveitis: Genetics, Clinical & Therapeutic Aspects

6:00PM-7:00PM: Abstract Number: 057

A “High-Risk” Depression/Fatigue Profile May Be Associated with Stronger Response to a Psychological Treatment for Childhood-Onset Systemic Lupus Erythematosus (cSLE)

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 056

An Advanced Physiotherapist Practitioner Model of Care Is Ideally Suited to Address Workforce Concerns in Pediatric Rheumatology: A Retrospective Chart Review

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 080

Analysis of Proteasomal Activity – a Potential Diagnostic Tool for Proteasome-associated Autoinflammatory Syndromes (PRAAS)

Posters: Genetics and Pathogenesis I

6:00PM-7:00PM: Abstract Number: 060

Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 062

Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 053

Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 067

Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 047

Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 077

Clinical Characteristics of Chronic Recurrent Multifocal Osteomyelitis or Chronic Nonbacterial Osteomyelitis in Pediatrics; Single Center Study in Korea

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 074

Clinical Characteristics of Juvenile Systemic Sclerosis in Korea: A 30-year Single Center Study

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 071

Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort

Posters: Clinical and Therapeutic I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].